Wells Fargo analyst Nathan Treybeck maintains $PROCEPT BioRobotics (PRCT.US)$ with a buy rating, and adjusts the target price from $69 to $112.
According to TipRanks data, the analyst has a success rate of 72.7% and a total average return of 39.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $PROCEPT BioRobotics (PRCT.US)$'s main analysts recently are as follows:
Procept BioRobotics provides a clinically distinctive treatment for patients with enlarged prostates, often afflicted by lower urinary tract symptoms. The analysis suggests there is significant market penetration potential remaining for PRCT, with only 8% penetration achieved today, indicating a substantial opportunity for future growth.
Analysts note that aquablation is still in the early stages of adoption, which is anticipated to be boosted by a new product cycle. Procept BioRobotics has indicated comfort with the 2025 consensus estimates and has been receiving generally positive feedback from physicians regarding Hydros.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
富国集团分析师Nathan Treybeck维持$PROCEPT BioRobotics (PRCT.US)$买入评级，并将目标价从69美元上调至112美元。
根据TipRanks数据显示，该分析师近一年总胜率为72.7%，总平均回报率为39.5%。
此外，综合报道，$PROCEPT BioRobotics (PRCT.US)$近期主要分析师观点如下：
Procept BioRobotics为患有肥大前列腺症状的患者提供具有临床特色的治疗方法，通常饱受下尿路症状的困扰。分析表明，PRCt仍具有显著的市场渗透潜力，目前仅实现了8%的渗透率，这表明未来增长有巨大机会。
分析师指出，气泡消融技术还处于早期阶段，预计将受到新产品周期的推动。Procept BioRobotics表示对2025年的共识估计感到满意，并且一直在收到医生们对Hydros的普遍积极反馈。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
